Resverlogix Corp Stock Fundamentals
RVXCF Stock | USD 0.04 0.00 0.00% |
Resverlogix Corp fundamentals help investors to digest information that contributes to Resverlogix Corp's financial success or failures. It also enables traders to predict the movement of Resverlogix Pink Sheet. The fundamental analysis module provides a way to measure Resverlogix Corp's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Resverlogix Corp pink sheet.
Resverlogix |
Resverlogix Corp Company Return On Asset Analysis
Resverlogix Corp's Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Current Resverlogix Corp Return On Asset | -0.96 |
Most of Resverlogix Corp's fundamental indicators, such as Return On Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Resverlogix Corp is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
Competition |
Based on the latest financial disclosure, Resverlogix Corp has a Return On Asset of -0.9632. This is 88.99% lower than that of the Biotechnology sector and 95.92% lower than that of the Health Care industry. The return on asset for all United States stocks is notably higher than that of the company.
Resverlogix Corp Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Resverlogix Corp's current stock value. Our valuation model uses many indicators to compare Resverlogix Corp value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Resverlogix Corp competition to find correlations between indicators driving Resverlogix Corp's intrinsic value. More Info.Resverlogix Corp is rated below average in return on asset category among its peers. It is rated below average in current valuation category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Resverlogix Corp's earnings, one of the primary drivers of an investment's value.Resverlogix Return On Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Resverlogix Corp's direct or indirect competition against its Return On Asset to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Resverlogix Corp could also be used in its relative valuation, which is a method of valuing Resverlogix Corp by comparing valuation metrics of similar companies.Resverlogix Corp is currently under evaluation in return on asset category among its peers.
Resverlogix Fundamentals
Return On Asset | -0.96 | |||
Current Valuation | 36.3 M | |||
Shares Outstanding | 265.27 M | |||
Shares Owned By Insiders | 44.51 % | |||
Price To Earning | 11.36 X | |||
EBITDA | (22.93 M) | |||
Net Income | (24.77 M) | |||
Cash And Equivalents | 42 K | |||
Total Debt | 53.27 M | |||
Current Ratio | 0.14 X | |||
Book Value Per Share | (0.23) X | |||
Cash Flow From Operations | (8.02 M) | |||
Earnings Per Share | (0.11) X | |||
Number Of Employees | 22 | |||
Beta | 0.52 | |||
Market Capitalization | 42.39 M | |||
Total Asset | 9.98 M | |||
Z Score | -6.6 | |||
Net Asset | 9.98 M |
About Resverlogix Corp Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Resverlogix Corp's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Resverlogix Corp using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Resverlogix Corp based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for disease states with high unmet medical needs. Resverlogix Corp. has a partnership with Eversana Life Science Services, LLC to support the pending launch of the commercialization of apabetalone for Covid-19 in the United States and Canada. RESVERLOGIX CORP operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 22 people.
Currently Active Assets on Macroaxis
Other Information on Investing in Resverlogix Pink Sheet
Resverlogix Corp financial ratios help investors to determine whether Resverlogix Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Resverlogix with respect to the benefits of owning Resverlogix Corp security.